# Bolt Biotherapeutics, Inc.: financial statements, quarterly

BOLT · Nasdaq · CIK 1641281 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bolt.md) · [Financials](/companies/bolt/financials.md) · [Filings](/companies/bolt/filings.md) · [Insiders](/companies/bolt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bolt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.5](/filings/0000950170-24-125413.md) | [2.1 d](/filings/0000950170-25-043873.md) | [5.3](/filings/0000950170-25-069188.md) | [1.3](/filings/0001641281-25-000007.md) | [1.1](/filings/0001193125-25-277549.md) | [0.0 d](/filings/0001193125-26-104121.md) | [1.2](/filings/0001193125-26-219382.md) | [1.8](/filings/0001193125-26-344597.md) | [2.2](/filings/0001193125-25-277549.md) | [2.5 d](/filings/0001193125-26-104121.md) | [0.0](/filings/0001193125-26-219382.md) | [0.0](/filings/0001193125-26-344597.md) |
| Research and development | $m | [15.0](/filings/0000950170-24-125413.md) | [16.3 d](/filings/0000950170-25-043873.md) | [16.5](/filings/0000950170-25-069188.md) | [15.4](/filings/0001641281-25-000007.md) | [13.8](/filings/0001193125-25-277549.md) | [11.7 d](/filings/0001193125-26-104121.md) | [9.5](/filings/0001193125-26-219382.md) | [7.5](/filings/0001193125-26-344597.md) | [6.5](/filings/0001193125-25-277549.md) | [5.0 d](/filings/0001193125-26-104121.md) | [4.8](/filings/0001193125-26-219382.md) | [5.1](/filings/0001193125-26-344597.md) |
| Operating income | $m | [(18.2)](/filings/0000950170-24-125413.md) | [(19.8) d](/filings/0000950170-25-043873.md) | [(17.1)](/filings/0000950170-25-069188.md) | [(22.6)](/filings/0001641281-25-000007.md) | [(16.4)](/filings/0001193125-25-277549.md) | [(16.9) d](/filings/0001193125-26-104121.md) | [(12.1)](/filings/0001193125-26-219382.md) | [(9.2)](/filings/0001193125-26-344597.md) | [(7.7)](/filings/0001193125-25-277549.md) | [(7.1) d](/filings/0001193125-26-104121.md) | [(7.6)](/filings/0001193125-26-219382.md) | [(8.4)](/filings/0001193125-26-344597.md) |
| Net income | $m | [(16.3)](/filings/0000950170-24-125413.md) | [(17.9) d](/filings/0000950170-25-043873.md) | [(10.8)](/filings/0000950170-25-069188.md) | [(21.2)](/filings/0001641281-25-000007.md) | [(15.2)](/filings/0001193125-25-277549.md) | [(15.9) d](/filings/0001193125-26-104121.md) | [(11.0)](/filings/0001193125-26-219382.md) | [(8.6)](/filings/0001193125-26-344597.md) | [(7.1)](/filings/0001193125-25-277549.md) | [(6.6) d](/filings/0001193125-26-104121.md) | [(7.2)](/filings/0001193125-26-219382.md) | [(7.7)](/filings/0001193125-26-344597.md) |
| Diluted EPS | $ per share | [(0.43)](/filings/0000950170-24-125413.md) | not reported | [(0.28)](/filings/0000950170-25-069188.md) | [(11.12)](/filings/0001641281-25-000007.md) | [(7.93)](/filings/0001193125-25-277549.md) | not reported | [(5.76)](/filings/0001193125-26-219382.md) | [(4.46)](/filings/0001193125-26-344597.md) | [(3.72)](/filings/0001193125-25-277549.md) | not reported | [(4.31)](/filings/0001193125-26-219382.md) | [(4.57)](/filings/0001193125-26-344597.md) |
| Basic EPS | $ per share | [(0.43)](/filings/0000950170-24-125413.md) | not reported | [(0.28)](/filings/0000950170-25-069188.md) | [(11.12)](/filings/0001641281-25-000007.md) | [(7.93)](/filings/0001193125-25-277549.md) | not reported | [(5.76)](/filings/0001193125-26-219382.md) | [(4.46)](/filings/0001193125-26-344597.md) | [(3.72)](/filings/0001193125-25-277549.md) | not reported | [(4.31)](/filings/0001193125-26-219382.md) | [(4.57)](/filings/0001193125-26-344597.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.2](/filings/0000950170-24-125413.md) | [10.8](/filings/0000950170-25-043873.md) | [4.3](/filings/0000950170-25-069188.md) | [6.2](/filings/0001641281-25-000007.md) | [9.4](/filings/0001193125-25-277549.md) | [7.2](/filings/0001193125-26-104121.md) | [8.4](/filings/0001193125-26-219382.md) | [9.6](/filings/0001193125-26-344597.md) | [17.8](/filings/0001193125-25-277549.md) | [11.7](/filings/0001193125-26-344597.md) | [11.6](/filings/0001193125-26-219382.md) | [12.9](/filings/0001193125-26-344597.md) |
| Current assets | $m | [125](/filings/0000950170-23-062048.md) | [106](/filings/0000950170-25-043873.md) | [95.1](/filings/0000950170-24-059564.md) | [76.6](/filings/0000950170-24-096200.md) | [57.1](/filings/0000950170-24-125413.md) | [50.8](/filings/0001193125-26-104121.md) | [42.5](/filings/0000950170-25-069188.md) | [38.3](/filings/0001641281-25-000007.md) | [35.6](/filings/0001193125-25-277549.md) | [30.3](/filings/0001193125-26-344597.md) | [25.8](/filings/0001193125-26-219382.md) | [20.6](/filings/0001193125-26-344597.md) |
| Total assets | $m | [175](/filings/0000950170-23-062048.md) | [160](/filings/0000950170-25-043873.md) | [143](/filings/0000950170-24-059564.md) | [124](/filings/0000950170-24-096200.md) | [109](/filings/0000950170-24-125413.md) | [99.6](/filings/0001193125-26-104121.md) | [85.9](/filings/0000950170-25-069188.md) | [75.5](/filings/0001641281-25-000007.md) | [65.1](/filings/0001193125-25-277549.md) | [56.7](/filings/0001193125-26-344597.md) | [48.0](/filings/0001193125-26-219382.md) | [40.3](/filings/0001193125-26-344597.md) |
| Current liabilities | $m | [18.8](/filings/0000950170-23-062048.md) | [20.5](/filings/0000950170-25-043873.md) | [16.7](/filings/0000950170-24-059564.md) | [17.9](/filings/0000950170-24-096200.md) | [18.1](/filings/0000950170-24-125413.md) | [15.9](/filings/0001193125-26-104121.md) | [13.6](/filings/0000950170-25-069188.md) | [12.3](/filings/0001641281-25-000007.md) | [10.0](/filings/0001193125-25-277549.md) | [8.4](/filings/0001193125-26-344597.md) | [7.3](/filings/0001193125-26-219382.md) | [7.9](/filings/0001193125-26-344597.md) |
| Total liabilities | $m | [47.1](/filings/0000950170-23-062048.md) | [47.0](/filings/0000950170-25-043873.md) | [38.7](/filings/0000950170-24-059564.md) | [38.3](/filings/0000950170-24-096200.md) | [37.3](/filings/0000950170-24-125413.md) | [42.4](/filings/0001193125-26-104121.md) | [39.1](/filings/0000950170-25-069188.md) | [36.7](/filings/0001641281-25-000007.md) | [33.0](/filings/0001193125-25-277549.md) | [30.2](/filings/0001193125-26-344597.md) | [28.2](/filings/0001193125-26-219382.md) | [27.7](/filings/0001193125-26-344597.md) |
| Shareholders' equity | $m | [128](/filings/0000950170-24-125413.md) | [113](/filings/0001193125-26-104121.md) | [104](/filings/0001641281-25-000007.md) | [85.9](/filings/0001193125-25-277549.md) | [72.0](/filings/0001193125-25-277549.md) | [57.2](/filings/0001193125-26-344597.md) | [46.8](/filings/0001193125-26-344597.md) | [38.8](/filings/0001193125-26-344597.md) | [32.1](/filings/0001193125-25-277549.md) | [26.5](/filings/0001193125-26-344597.md) | [19.8](/filings/0001193125-26-344597.md) | [12.6](/filings/0001193125-26-344597.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(16.7) d](/filings/0000950170-24-125413.md) | [(14.3) d](/filings/0000950170-25-043873.md) | [(16.8)](/filings/0000950170-25-069188.md) | [(16.1) d](/filings/0001641281-25-000007.md) | [(14.0) d](/filings/0001193125-25-277549.md) | [(14.4) d](/filings/0001193125-26-104121.md) | [(13.4)](/filings/0001193125-26-219382.md) | [(9.6) d](/filings/0001193125-26-344597.md) | [(9.7) d](/filings/0001193125-25-277549.md) | [(7.2) d](/filings/0001193125-26-104121.md) | [(8.0)](/filings/0001193125-26-219382.md) | [(6.5) d](/filings/0001193125-26-344597.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-125413.md) | [0.0 d](/filings/0000950170-25-043873.md) | [0.0](/filings/0000950170-24-059564.md) | [0.0 d](/filings/0000950170-24-096200.md) | [0.0 d](/filings/0001193125-25-277549.md) | [0.0 d](/filings/0001193125-26-104121.md) | not reported | not reported | [0.1 d](/filings/0001193125-25-277549.md) | [0.0 d](/filings/0001193125-26-104121.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [37.5](/filings/0000950170-23-062048.md) | [37.7](/filings/0000950170-24-059564.md) | [37.8](/filings/0000950170-24-096200.md) | [37.9](/filings/0000950170-24-125413.md) | [38.1](/filings/0000950170-25-069188.md) | [1.9](/filings/0001641281-25-000007.md) | [1.9](/filings/0001193125-25-277549.md) | [1.9](/filings/0001193125-26-219382.md) | [1.9](/filings/0001193125-26-344597.md) | [1.9](/filings/0001193125-25-277549.md) | [1.7](/filings/0001193125-26-219382.md) | [1.7](/filings/0001193125-26-344597.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,926,345 at 2026-08-04, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344597.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.